All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.


Update on Sterile Compounding in Health Systems: Opportunities and Challenges

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.

NOTE: If you attended the live CE activity titled "Update on Sterile Compounding in Health Systems: Opportunities and Challenges" that was held on June 6, 2017 (on-site in Minneapolis, Minnesota or via the concurrent webinar), AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-0000-17-140-L03-P), you are NOT eligible to also receive CE credit for this home-study activity.

Activity Description

The regulations for sterile IV compounding continue to be updated and revised. The pharmacy department leadership, along with their staff, are responsible for ensuring compliance with these standards to protect patients and provide quality care. Staying up-to-date with these standards can be challenging and time consuming. State and federal agencies along with accreditation services are now monitoring for full compliance with these regulations during inspections. This educational session will review the revised and new USP Chapter <797> and <800> standards to help ensure compliance. The importance of batch testing and an overview of how that is accomplished will also be reviewed. Pharmacy department leadership strategies to maintain compliance with the standards will also be discussed. The activity will conclude with a panel discussion to address audience questions.

Learning Objectives

The target audience for this activity includes pharmacy administrators, compounding pharmacists, and pharmacists in health-system settings. At the completion of this symposium, the participant will be able to:

  • Describe the current landscape of the United States Pharmacopeia (USP) Compounding Chapters.
  • Identify the environmental control requirements for sterile compounding.
  • Describe batch testing and the role batch testing can play to increase the safety of sterile compounding.
  • Discuss health system pharmacy accountability related to sterile compounding procedures.
  • Outline pharmacy leadership strategies for managing the increasing regulated environment while providing optimal patient care services.


Louis S. Diorio, RPh, FAPhA
LDT Health Solutions, Inc.
Wayne, New Jersey

Fred Massoomi, Pharm.D., FASHP
Senior Director of Health-system & Hospital Services
Visante, Inc.
Omaha, Nebraska

Susan J. Schniepp
Distinguished Fellow
Regulatory Compliance Associates, Inc.
Albuquerque, New Mexico

CE Accreditation

Release Date: 6-6-2017
Expiration Date: 7-31-2018


ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-17-140-H03-P has been assigned to this home-study knowledge-based activity (initial release date 6-6-17). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Mr. Diorio is an employee and shareholder of LDT Health Solutions, Inc. and has served as a speaker for Grifols USA and Spectrum Pharmacy Products. Dr. Massoomi is an employee - consultant for Visante, Inc. and has served as a speaker for Baxter, Equashield, Hospira, and ICU Medical, and as a writer for BD. Ms. Schniepp has served as a consultant for Regulatory Compliance Associates, as an auditor for NSF, and as a consultant for PharMEDium Services, LLC. Content review and conflict resolution conducted by James Dorociak, PharmD, MSc. Dr. Dorociak has no relevant financial relationships to disclose. A portion of grant funds received by ProCE from PharMEDium Services, LLC will be used to compensate the faculty for this presentation.

Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.


This CE activity is supported by an educational grant from PharMEDium Services, LLC.


The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Download Handout